{"id":4293,"date":"2017-08-12T11:12:57","date_gmt":"2017-08-12T11:12:57","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/2017\/08\/12\/quasi-feasibility-studycase-control-associating-deep-local-hyperthermia-treatment-with-standard-cancer-treatments-and-describing-patterns-of-response-esho-poster\/"},"modified":"2025-09-04T13:41:42","modified_gmt":"2025-09-04T13:41:42","slug":"klinik-calismasi-hipertermi-2","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/tr\/klinik-calismasi-hipertermi-2\/","title":{"rendered":"Derin lokal hipertermi tedavisini standart kanser tedavileriyle ili\u015fkilendiren ve yan\u0131t modellerini tan\u0131mlayan yar\u0131 uygulanabilirlik klinik \u00e7al\u0131\u015fmas\u0131"},"content":{"rendered":"

Derin lokal hipertermi tedavisini standart kanser tedavileriyle ili\u015fkilendiren ve yan\u0131t modellerini tan\u0131mlayan yar\u0131 uygulanabilirlik klinik \u00e7al\u0131\u015fmas\u0131<\/span><\/span><\/a><\/h1>\n

Andromedic hipertermi klinik \u00e7al\u0131\u015fmas\u0131 – Avrupa Hipertermik Onkoloji Derne\u011fi kongresi 2014\u00a0<\/span><\/span><\/a><\/h2>\n
\"Klinik
Yar\u0131 fizibilite \u00e7al\u0131\u015fmas\u0131 (vaka kontrol\u00fc) derin lokal hipertermi HyDeep 600WM tedavisini standart kanser tedavileriyle kar\u015f\u0131la\u015ft\u0131rarak yan\u0131t modellerini tan\u0131ml\u0131yor<\/span><\/span><\/figcaption><\/figure>\n

Girii\u015f:<\/span><\/span><\/strong><\/p>\n

Bu, \u0130spanya ve End\u00fcl\u00fcs’te derin lokal hipertermiyi standart kanser tedavileriyle birle\u015ftiren ilk klinik \u00e7al\u0131\u015fmad\u0131r.<\/span><\/span><\/p>\n

Materyaller ve Y\u00f6ntemler:<\/span><\/span><\/strong><\/p>\n

Ama\u00e7lar:<\/span><\/span><\/strong><\/p>\n

Birincisi:<\/span><\/span><\/strong> Kamu sa\u011fl\u0131k sistemi i\u00e7erisinde hiperterminin standart kanser tedavileriyle birlikte uygulanmas\u0131n\u0131n klinik yararlar\u0131n\u0131, tedavi yan\u0131t\u0131n\u0131, tedavi uygulanabilirli\u011fini ve konforunu analiz etmek. <\/span><\/span>
\n\u0130kincisi:<\/span><\/span><\/strong> Sa\u011f kal\u0131m\u0131, ya\u015fam kalitesini ve toksisiteyi (genel ve spesifik kanser hipertermisi) analiz etmek.<\/span><\/span><\/p>\n

Tasar\u0131m:<\/span><\/span><\/strong> Hipertermi tedavilerinin (haftada 2-3 seans olmak \u00fczere 6-10 seans) standart radyoterapi (RT), kemoterapi (BT) veya her ikisinin kombinasyonu ile birlikte uyguland\u0131\u011f\u0131 prospektif, yar\u0131 deneysel, vaka-kontrol \u00e7al\u0131\u015fmas\u0131. Dokuz yerle\u015fimli primer t\u00fcm\u00f6rleri veya radikal veya kombine tedavi uygulanan metastatik t\u00fcm\u00f6rleri olan hastalar, bir \u00f6nceki y\u0131l i\u00e7inde tedavi g\u00f6rm\u00fc\u015f iki kontrol vakas\u0131yla retrospektif olarak kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131.<\/span><\/span><\/p>\n

\u0130ki faz:<\/span><\/span><\/strong> Birinci \u00f6\u011frenme faz\u0131 (20 hasta). \u0130kinci aktif tedavi faz\u0131, 97 hastan\u0131n kat\u0131l\u0131m\u0131yla, 2012 y\u0131l\u0131nda her iki hastanede hipertermi olmaks\u0131z\u0131n radyoterapi veya QT interval terapisi uygulanan 196 kontrolle kar\u015f\u0131la\u015ft\u0131r\u0131ld\u0131 (toplam 293 hasta).<\/span><\/span><\/p>\n

Dokuz t\u00fcm\u00f6r yeri:<\/span><\/span><\/strong><\/p>\n

\n
    \n
  • Rahim a\u011fz\u0131, prostat, mesane<\/span><\/span><\/li>\n
  • Pankreas, ameliyat edilemeyen ba\u015f ve boyun<\/span><\/span><\/li>\n
  • Beyin t\u00fcm\u00f6rleri, ameliyat \u00f6ncesi rektum<\/span><\/span><\/li>\n
  • \u0130leri evre meme kanserinde ameliyat edilemeyen neoadjuvan tedavi<\/span><\/span><\/li>\n
  • K\u00fc\u00e7\u00fck h\u00fccreli olmayan akci\u011fer kanseri (KHDAK)<\/span><\/span><\/li>\n
  • Farkl\u0131 b\u00f6lgelerde palyatif tedavi<\/span><\/span><\/li>\n<\/ul>\n<\/blockquote>\n

    Sonu\u00e7lar:<\/span><\/span><\/strong><\/p>\n

    Listeden ilk veriler:<\/span><\/span><\/strong> 22 hasta (9’u Juan Roman Jimenez Hastanesi’nde, 13’\u00fc Carlos Haya Hastanesi’nde).<\/span><\/span><\/p>\n

    Cinsiyet: 13 erkek ve 9 kad\u0131n.<\/span><\/span><\/p>\n

    Ortalama ya\u015f: 55 y\u0131l (34-76 y\u0131l).<\/span><\/span><\/p>\n

    T\u00fcm\u00f6r yeri: Glioblastoma (2c), ba\u015f ve boyun (7c), ameliyat \u00f6ncesi rektum (3c), meme (3c1), akci\u011fer (11c), prostat (4c), serviks (lc), sakroiliak kemik metastaz\u0131.<\/span><\/span><\/p>\n

    Tedavi:<\/span><\/span><\/strong> Standart onkoloji tedavisi ile ili\u015fkili b\u00f6lgeye ba\u011fl\u0131 olarak 150W ile 400W aras\u0131nda g\u00fc\u00e7 kullan\u0131larak, haftada 2-3 kez, 1 saat s\u00fcren 10 seans HyDeep 600WM hipertermi cihaz\u0131 (Andromedic) uygulan\u0131r.<\/span><\/span><\/p>\n

    Tedavinin kesilme nedenleri:<\/span><\/span><\/strong><\/p>\n

    Huelva’daki Juan R Jim\u00e9nez Hastanesi: 3 vaka, tedavi yerine enfeksiyon (rektal kanserde sel\u00fclit), rahim kanamas\u0131 (serviks kanseri) ve g\u00f6n\u00fcll\u00fc olarak tedavinin kesilmesi.<\/span><\/span><\/p>\n

    Melaga C Haya Hastanesi: 2 hasta, 1’i 6. seansta iyi tolere etti ve bir di\u011feri de iyi tolere edilen ilerleme nedeniyle 6. seansta.<\/span><\/span><\/p>\n

    Hasta Sonucu:<\/span><\/span><\/strong> 19 hasta hayatta olup yan\u0131t de\u011ferlendirmesini beklemektedir ve 3 hasta hastal\u0131\u011f\u0131n ilerlemesi nedeniyle \u00f6lm\u00fc\u015ft\u00fcr (2 hasta daha \u00f6nce \u0131\u015f\u0131nlanm\u0131\u015f ba\u015f ve boyun b\u00f6lgesinde t\u00fcm\u00f6r n\u00fcks\u00fc nedeniyle sadece kemoterapi ve HT almakta olup, faringeal t\u00fcm\u00f6r n\u00fcks\u00fc olan bir di\u011fer hasta ise palyatif RT ve HT almaktad\u0131r).<\/span><\/span><\/p>\n

    Tolerans: Hastalar\u0131n %81,2’si (18 ki\u015fi) memnun veya \u00e7ok memnun olduklar\u0131n\u0131 belirtirken, %18,8’i (4 ki\u015fi) kabul edilebilir olduklar\u0131n\u0131 belirtti.<\/span><\/span><\/strong><\/p>\n

    Toksisite: 22 hastan\u0131n 8’inde (%36,3) 1. derece yanma benzeri toksisite meydana geldi. %66,6’s\u0131nda toksisite g\u00f6r\u00fclmedi. Bir hastada tedavi b\u00f6lgesinde 1. derece a\u011fr\u0131\/\u00f6n kar\u0131\u015f\u0131m (\u00fclserli memede) g\u00f6r\u00fcld\u00fc.<\/span><\/span><\/strong><\/p>\n

    \u00d6n deneyimlerimiz, kamu hastanesi ortam\u0131nda, rutin bak\u0131mda, ola\u011fan\u00fcst\u00fc kaynaklara ihtiya\u00e7 duyulmadan ve y\u00fcksek toleransla tedavinin uygulanabilirli\u011fini g\u00f6stermektedir.<\/span><\/span><\/strong><\/p>\n

    SONU\u00c7LAR: Kamu sa\u011fl\u0131k sistemindeki hastalar\u0131m\u0131z\u0131n %81,2’si i\u00e7in tedavi uygulanabilir ve konforludur; %33’\u00fcnde g\u00f6r\u00fclen hafif toksisite hipertermi tedavisine ba\u011fl\u0131d\u0131r. Uygun hasta se\u00e7imi \u00e7ok \u00f6nemlidir.<\/span><\/span><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

    Derin lokal hipertermi tedavisini standart kanser tedavileriyle ili\u015fkilendiren ve yan\u0131t modellerini tan\u0131mlayan yar\u0131 uygulanabilirlik klinik \u00e7al\u0131\u015fmas\u0131 Andromedic hipertermi klinik \u00e7al\u0131\u015fmas\u0131 – Avrupa Hipertermik Onkoloji Derne\u011fi kongresi 2014\u00a0 Girii\u015f: Bu, \u0130spanya ve End\u00fcl\u00fcs’te derin lokal hipertermiyi standart kanser tedavileriyle birle\u015ftiren ilk klinik \u00e7al\u0131\u015fmad\u0131r. Materyaller ve Y\u00f6ntemler: Ama\u00e7lar: Birincisi: Kamu sa\u011fl\u0131k sistemi i\u00e7erisinde hiperterminin standart kanser tedavileriyle…<\/p>\n","protected":false},"author":1,"featured_media":1953,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[197,1031],"tags":[],"class_list":["post-4293","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-tr","category-studii-clinice-tr"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/posts\/4293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/comments?post=4293"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/posts\/4293\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/media\/1953"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/media?parent=4293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/categories?post=4293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/tr\/wp-json\/wp\/v2\/tags?post=4293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}